1502 Viceroy Drive
Dallas, TX 75235
Phone: 214-648-3898
www.cumbre.net

Bob England, president and CEO
Privately Held

Overview

In February 2001 Cumbre Inc. was spun off from Tularik Inc., of South San Francisco, to develop chemistry, biology and drug screening. Cumbre’s scientific platform combines proteomics-based drug discovery with target-directed screens and an advanced lead compound series.

Tularik continues to be a significant shareholder in Cumbre, though the stake has not been disclosed. Cumbre, which means “summit” in Spanish, originally was named Tularik Texas Corp. Cumbre still has access to Tularik’s screening libraries of about 350,000 compounds, as well as its bioinformatics database.

The technology was developed at the University of Texas Southwestern Medical Center at Dallas and Cumbre has licensed the know-how associated with it to continue development. Cumbre is renovating space near the medical center.

In September 2001, Cumbre raised $26 million in a second round of financing to support its programs in antibiotic and antifungal drug discovery.

Partners

High-throughput drug screening technology: University of Texas Southwestern Medical Center at Dallas

Bioinformatics database and library access: Tularik Inc.